Pfizer outlook improves beyond COVID as cost cuts target $2.7B by 2029, though patents and pricing pose risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results